SC 13D

Company

Design Therapeutics, Inc.

Filed

April 9, 2021

Accession Number

0001193125-21-111505

A Schedule 13D is filed when an investor acquires more than 5% of a company's shares with an intent to influence control. Learn more about SC 13D filings →